Sun Pharma rises on getting nod to manufacture, market generic semaglutide in South Africa
Sun Pharmaceutical Industries is currently trading at Rs. 1959.50, up by 19.35 points or 1.00% from its previous closing of Rs. 1940.15 on the BSE.
The scrip opened at Rs. 1954.95 and has touched a high and low of Rs. 1960.00 and Rs. 1944.85 respectively. So far 29811 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1953.75 on 10-Jul-2026 and a 52 week low of Rs. 1547.25 on 26-Sep-2025.
Last one week high and low of the scrip stood at Rs. 1,960.00 and Rs. 1887.85 respectively. The current market cap of the company is Rs. 469765.79 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 37.04% and 8.48% respectively.
Sun Pharmaceutical Industries has secured approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. The company plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing.
South Africa faces a growing burden of type 2 diabetes, driven in part by rapid urbanization and changing lifestyles. This rising prevalence places significant pressure on patients and healthcare services. Improving access to effective therapies is therefore an important component of addressing this national health challenge.
